I det første, placebokontrollerede kliniske forsøg var Fabrazyme effektivt til clearance af GL- 3 fra det vaskulære endotel i nyrerne efter 20 ugers behandling.
In the first placebo-controlled clinical trial, Fabrazyme was effective in clearing GL-3 from the vascular endothelium of the kidney after 20 weeks of treatment.